Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd (PPBT) is a clinical-stage oncology innovator developing therapies to combat tumor resistance mechanisms. This hub provides investors and researchers with timely updates on the company’s pipeline progress, including its dual inhibitor NT219, CEACAM1-targeting CM24 antibody, and tri-specific antibody platform.
Key resources include: Press releases detailing clinical trial milestones for lead candidates, partnership announcements with pharmaceutical collaborators, and regulatory filings related to drug development. Users will find analysis of preclinical data alongside updates on combination therapy strategies involving immunotherapies.
Bookmark this page to efficiently track PPBT’s advancements in overcoming immune evasion through novel mechanisms like STAT3 inhibition and localized immune activation. Check regularly for new insights into trial designs, biomarker analyses, and strategic initiatives shaping the future of precision oncology.
Purple Biotech (NASDAQ/TASE: PPBT) has appointed Shai Lankry as its new Chief Financial Officer. Lankry brings over 20 years of financial leadership experience in biotech and healthcare sectors. His notable career includes serving as CFO of Gamida Cell Ltd. (2018-2023), Finance Director at West Pharmaceutical Services (2016-2018), and CFO at MacroCure Ltd. (2013-2017), where he successfully led a U.S. IPO and M&A transaction with Leap Therapeutics.
Most recently, Lankry operated his own consulting firm, LS Consulting Services. He holds an M.B.A. in Finance from Tel-Aviv University and is a licensed Israeli CPA. The appointment comes as Purple Biotech, a clinical-stage company developing first-in-class therapies for tumor immune evasion and drug resistance, advances its pipeline into late-stage trials.
Purple Biotech announced final data from its Phase 2 study of CM24 in pancreatic cancer patients at AACR 2025. The study showed significant efficacy in biomarker-enriched subgroups, with up to 90% reduction in death risk in specific patient populations.
Key findings include:
- 78% reduction in death risk for patients with specific CEACAM1 ranges
- 61% reduction in death risk for patients with defined CEACAM1 or MPO levels
- 90% reduction in death risk for patients with high tumor CEACAM1 and low PD-L1 CPS
The combination therapy of CM24, nivolumab, and chemotherapy was well-tolerated and showed improvements in all efficacy measures. The study identified CEACAM1 as a potential biomarker, both in serum and tumor tissue. Based on these results, Purple Biotech plans to conduct a biomarker-driven Phase 2b study, potentially expanding into gastric and biliary tract cancer treatments.
Purple Biotech (NASDAQ/TASE: PPBT) presented new data for NT219, their dual inhibitor of IRS1/2 and STAT3, at AACR 2025. The company revealed positive findings from two posters focusing on colorectal and head and neck cancers.
Key findings include:
- NT219 shows potential in overcoming immune evasion mechanisms and restoring immunotherapy efficacy in head and neck squamous cell carcinoma (HNSCC)
- Upregulation of pIGF1R and pSTAT3 correlated with patient response, suggesting potential biomarkers
- In colorectal cancer, APC-loss or enhanced wnt/β-catenin signaling may serve as biomarkers for NT219 treatment effectiveness
- The drug demonstrated ability to reverse chemo-resistance and synergize with approved chemotherapy in multiple models
Purple Biotech (NASDAQ/TASE: PPBT) announced the publication of a study in Neuro Oncology journal demonstrating NT219's potential to suppress brain metastasis in colorectal cancer. The research, conducted at Tel Aviv University and Sourasky Medical Center, reveals that NT219 combined with 5-flourouracil (5-FU) effectively inhibits colorectal cancer brain metastasis through the IRS2 pathway.
The study analyzed over 35,000 colorectal cancer samples, identifying IRS2 as a key driver of brain metastasis. NT219, a first-in-class small molecule drug, works by degrading IRS1/2 and blocking downstream signaling. The research shows particular promise for colorectal cancer patients, of whom 20% have distant metastasis at diagnosis and 50% develop metastasis later.
Purple Biotech is advancing NT219 into a Phase 2 study for recurrent/metastatic squamous cell carcinoma of the head and neck, with potential expansion into colorectal and other cancers.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on developing first-in-class therapies for tumor immune evasion and drug resistance, has announced its participation in the Canaccord Genuity Horizons in Oncology Virtual Conference.
CEO Gil Efron will join a panel discussion titled 'New Radiotherapy and Targeted Therapy Approaches' scheduled for April 7, 2025, from 2:00 PM to 2:50 PM ET. The company's management team will also be available for one-on-one meetings during the conference.
Purple Biotech (NASDAQ/TASE: PPBT) announced three poster presentations at the upcoming 2025 American Association for Cancer Research Meeting in Chicago from April 25-30. The presentations will showcase:
- Final analysis of Phase 2 cohort study of CM24 combined with nivolumab and chemotherapy in pancreatic cancer, including potential serum biomarkers
- Research on APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
- Study of NT219's ability to overcome immune evasion-resistant mechanisms in head and neck squamous cell carcinoma
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
